Table 2 Release of free SOR and SOR-MIL-53 over 48 h.

From: MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro

Time (h)

SOR only Release %

SOR-MIL-53 Release %

0

0 ± 0

0 ± 0

0.5

14.2 ± 2.4

17.85 ± 2.1

1

28.24 ± 3.1

32.17 ± 3.2

2

52.32 ± 3.5

51.27 ± 1.9

3

69.24 ± 3.23

59.42 ± 1.6

4

84.35 ± 2.2

66.49 ± 1.2

5

100

69.83 ± 1.1

6

 

69.99 ± 1

8

 

71.49 ± 1.1

10

 

72.93 ± 1.5

12

 

74.29 ± 1.7

24

 

83.34 ± 1.9

48

 

100% ± 12.7

Back to article page